Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review]

[Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Abstract Text:

    ping-ping luPing-Ping Lu,zhi-yun mengZhi-Yun Meng,ming-xiao zhouMing-Xiao Zhou,min-wei wangMin-Wei Wang,gui-fang douGui-Fang Dou,ping-ping luPing-Ping Lu,zhi-yun mengZhi-Yun Meng,ming-xiao zhouMing-Xiao Zhou,min-wei wangMin-Wei Wang,gui-fang douGui-Fang Dou,

    CD22 is a transmembrane sialoglycoprotein and a member of the immunoglobulin superfamily. Its expression is restricted to the B cell lineage and a vast majority of B cell NHLs. CD22 plays a key role in B cell development, survival, and function. Humanized anti-CD22 antibodies were developed to minimize the immunogenicity and to enhance effector interactions during their developments of diagnostic and immunotherapeutic agent. Preclinical test with anti-CD22 antibodies indicates that a single, conjugated or radiolabeled agent has shown preliminary antitumor activity in patients with recurrent and heavily pretreated NHL. Anti-CD22 antibodies were well tolerated, without dose-dependant toxicity. Anti-CD22 antibodies are currently being evaluated in combination with rituximab, and the early results suggest that the combination of the two antibodies are well tolerated and may result in better clinical activity than the single agent alone. Thus, anti-CD22 antibodies are theoretically good candidates alone and in combination with other drugs in the treatment of B cell malignancies. In this review, the physiologic function and characteristics of CD22 antigen as target molecule of guide therapy for NHL, the types of anti-CD22 antibodies in therapy of NHL and the combination use with other antibodies were summarized.

    [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Publishing Authors By Initials

    pp luPP Lu,zy mengZY Meng,mx zhouMX Zhou,mw wangMW Wang,gf douGF Dou,pp luPP Lu,zy mengZY Meng,mx zhouMX Zhou,mw wangMW Wang,gf douGF Dou,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Journal Published:

    PUBLICATION TYPE: Review

    Journal: Zhongguo shi yan xue ye xue za zhi / Zhongguo bing

    VOLUME: 14

    Page Numbers: 1258-61

    Journal Abbreviation: Zhongguo Shi Yan Xue Ye Xue Za

    ISSN: 1009-2137

    DAY: 5

    MONTH: Dec

    YEAR: 2006

    [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Information

    Number of References: 18

    LANGUAGE: chi

    NlmUniqueID: 101084424

    [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review]

    AFFILIATION: The Key Laboratcry of Pharmacokinetics, Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China.

    Country: China

    China Research PublicationChina Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Zhongguo Shi Yan Xue Ye Xue Za

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Immunotherapy of non-Hodgkin's lymphomas NHL by anti-CD22 antibody--review Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News